Stock Events

Stock Events

Regencell Bioscience 

$5.63
168
+$0.36+6.74%Monday 21:00
-$0.01-0.27%00:11After hours

Statistics

Day High
5.67
Day Low
5.19
52W High
69
52W Low
4.51
Volume
3,035
Avg. Volume
-
Mkt Cap
2.79B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Feb 2018
$0.01
Dec 2017
$0.01
Sep 2017
$0.01
Jun 2017
$0.01
Mar 2017
$0.01
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

Oct 31Expected
Q2 2020
Q3 2020
Q1 2021
Q3 2021
Q4 2021
Q1 2022
Q3 2022
-33.38
-22.25
-11.13
0
Expected EPS
0
Actual EPS
-0.3

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-11.7MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RGC. It's not an investment recommendation.
NVIDIA
37
NVDA
Tesla
27
TSLA
Microsoft
22
MSFT
Apple
20
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.86B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of biotechnology that overlaps with Regencell's focus on regenerative medicine, making them direct competitors in the biotech innovation space.
Editas Medicine
EDIT
Mkt Cap394.7M
Editas Medicine operates in the genome editing field, directly competing with Regencell in the development of treatments for genetic diseases and conditions.
Intellia Therapeutics
NTLA
Mkt Cap1.59B
Intellia Therapeutics is a leading developer of CRISPR/Cas9 gene-editing therapies, competing with Regencell in the race to develop genetic treatments.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.85B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, competing with Regencell in the broader biotech market.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.71B
Vertex Pharmaceuticals is known for its work in treating cystic fibrosis and other serious diseases, competing with Regencell in the market for innovative therapeutic solutions.
Alnylam Pharmaceuticals
ALNY
Mkt Cap20.89B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics, competing with Regencell in the field of genetic medicine.
Beam Therapeutics
BEAM
Mkt Cap2.73B
Beam Therapeutics focuses on precision genetic medicines using base editing, a form of gene editing, placing it in direct competition with Regencell's gene-based therapies.
Pfizer
PFE
Mkt Cap167.52B
Pfizer, a large pharmaceutical company, has been expanding its investment in biotechnology and gene therapy, making it a competitor to Regencell in the broader market for innovative treatments.

About

Regencell Bioscience Holdings Ltd is an early-stage bioscience company that focuses on research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, specifically ADHD and ASD. Its goal is to save and improve the lives of patients, their families and caregivers and become a market leader for the natural and holistic treatment globally. The company operates and manages its business as a single segment - in the research and development of the company's product candidates.
Show More
CEO
Yat-Gai Au
Employees
10
Country
Cayman Islands
ISIN
KYG7487R1002

Listings

BOATS
BOATS
RGC.BOATS
XNAS
US
RGC

0 Comments

Share your thoughts

FAQs

What is Regencell Bioscience stock price today?▼
The current price of RGC is $5.63 USD — it has increased by +6.74% in the past 24 hours. Watch Regencell Bioscience stock price performance more closely on the chart.
What is Regencell Bioscience stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Regencell Bioscience stocks are traded under the ticker RGC.
Is Regencell Bioscience stock price growing?▼
RGC stock has fallen by -8.54% compared to the previous week, the month change is a -23.47% fall, over the last year Regencell Bioscience has showed a -59.33% decrease.
What is Regencell Bioscience market cap?▼
Today Regencell Bioscience has the market capitalization of 2.79B
What were Regencell Bioscience earnings last quarter?▼
RGC earnings for the last quarter are -0.3 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Regencell Bioscience revenue for the last year?▼
Regencell Bioscience revenue for the last year amounts to 0 USD.
What is Regencell Bioscience net income for the last year?▼
RGC net income for the last year is -11.7M USD.
Does Regencell Bioscience pay dividends?▼
Yes, RGC dividends are paid quarterly. The last dividend per share was 0.01 . As of today, Dividend Yield (FWD)% is 0%.
How many employees does Regencell Bioscience have?▼
As of November 10, 2026, the company has 10 employees.
In which sector is Regencell Bioscience located?▼
Regencell Bioscience operates in the Health & Wellness sector.
When did Regencell Bioscience complete a stock split?▼
The last stock split for Regencell Bioscience was on June 16, 2025 with a ratio of 38:1.
Where is Regencell Bioscience headquartered?▼
Regencell Bioscience is headquartered in Hong Kong, Cayman Islands.